TABLE 1.
Clinical characteristics of participants.
| Indexes | Tumor patients | Reference range |
| Age (years) | 58.40 ± 2.36 | |
| Gender | ||
| Female | 10 (50%) | |
| Male | 10 (50%) | |
| Location of tumor | ||
| Proximal colon | 4(20%) | |
| Distal colon | 8 (40%) | |
| Rectum | 8 (40%) | |
| TNM | ||
| 0–II | 14 (70%) | |
| III–IV | 6 (30%) | |
| Blood pressure | ||
| Hypertension | 7 (35%) | |
| Normotension | 13 (65%) | |
| LNM | ||
| Yes | 6 (30%) | |
| No | 14 (70%) | |
| BMI, kg/m2 | 22.68 ± 3.53 | |
| Laboratory parameters (M ± Q) | ||
| Glu, mmol/L | 6.14 ± 1.50 | 3.90–6.10 |
| T-CH, mmol/L | 4.56 ± 0.63 | 3.10–5.71 |
| TG, mmol/L | 1.81 ± 0.35 | 0.58–1.70 |
| HDL, mmol/L | 1.25 ± 0.26 | 0.91–1.55 |
| LDL, mmol/L | 2.77 ± 0.47 | 2.07–3.12 |
| CEA, μg/L | 4.39 ± 5.97 | 0–5 |
| CA-19-9, U/ml | 155.09 ± 585.59 | 0–37 |
| TBA, μmol/L | 4.78 ± 4.87 | 0–10 |
| LDH, U/L | 180.30 ± 46.00 | 120.0–250.0 |
| ADA, U/L | 10.05 ± 3.08 | 0–25 |
| NEUT#, 109/L | 4.40 ± 1.49 | 1.8–6.3 |
| LY#, 109/L | 1.52 ± 0.44 | 1.1–3.2 |
| PLT, 109/L | 275.45 ± 78.40 | 125–350 |
| NLR | 3.35 ± 2.28 | |
| PLR | 199.43 ± 90.07 |
TNM, tumor–node–metastasis; LNM, lymph node metastasis; BMI, body mass index; Glu, glucose; T-CH, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 19-9; TBA, total bile acid; LDH, lactate dehydrogenase; ADA, adenosine deaminase; NEUT#, neutrophils; LY#, lymphocyte; PLT, platelet count; NLR, neutrophil–lymphocyte ratio; PRL, platelet-to-lymphocyte ratio.